CYTIMMUNE SCIENCES, INC. (CSI) is a company dedicated to improving the human condition. For the past ten years, CSI has established itself as a cutting edge technology-based research organization. With the rollout of their patented methods for measuring biological response to disease, CSI has gained progressive interest from both the research and pharmaceutical sectors. Currently, CSI is positioning itself for a public offering, currently funded by private investors. CSI provides a "for-research-only" product line which holds great promise for future diagnostic and clinical use. A brief overview follows:
The human body's immune system is coordinated by a network of molecules, called cytokines. Cytokines signal the immune system to combat diseases including AIDS, bacterial infections, cancer, influenza, rheumatoid arthritis and strep.
CSI is dedicated to the maintenance of health and combatting disease. CSI is currently developing patent pending technologies for: (1) offering biological response markers (BRMÃs) in humans that are invisible to other detection systems, (2) boosting cytokine levels through a Cytokine Carrier System' (CCS), which safely delivers large amounts of BRMÃs intravenously, and (3) reducing undesirable biological response levels in persons with diseases such as septic shock, rheumatoid arthritis, and osteoporosis.
Researchers are monitoring cytokines for some of the following diagnostic methodologies:
* Set dose regimens for cancer patients undergoing chemotherapy
* Monitor cancer patients for the early detection of secondary tumors
* Track HIV+ patients for the onset of AIDS and for disease progression
* Provide an index of immune status in autoimmune diseases, such as rheumatoid arthritis
* Add diagnostic information in evaluating allergy and asthma patients
* Discriminate between viral and bacterial infections, and early diagnosis of sepsis.
Monitoring Cytokines For Research Use
The first step in harnessing the power of cytokines is to measure their levels in biological fluids, such as blood, enabling physicians to monitor the status of the immune system. However, in the human body, most cytokines are bound to carrier proteins. Other commercial assays for measuring biological response cannot detect these bound cytokines. CSI has eliminated this problem by developing a patent pending single-binding detection system (the ACCUCYTE' immunoassay), which is able to measure bound cytokines. More than a dozen research publications have reported that ACCUCYTE' reproducibly demonstrated that BRMÃs of endogenous cytokines were at much higher levels than standard detection assays. Because the ACCUCYTE' system is the only system that measures both free and bound cytokines in biological samples, it is the only immunoassay system that can achieve the reproducibility and accuracy necessary to meet the FDA standards for a clinical diagnostic.
The Company has developed specific ACCUCYTE' kits for measuring a variety of endogenous cytokines. CSI is also marketing a line of more traditional kits for standard vitro measurement of BRMÃs (CYTELISA').
Contact: Phone 301-445-4220, Fax 301-445-4370
Niki Faldemolaei, Marketing Director, e-mail: [email protected]
Lawrence Tamarkin, PhD, President and CEO, e-mail: [email protected]
Leon Taub, Board of Directors
Giulio Paciotti, PhD, Director of Research and Development
------------------------------------------------------------------------
ACCUCYTE' Reference List
Picture: * Roberts, J. A. et al. "Cytokine and Lymphocyte Activation During Experimental Acute Pyelonephritis." Urol Res (1995) 23: 33-38. Picture: * Huang, Shau-Ku et al. "IL-13 Expression at the Sites of Allergen Challenge in Patients with Asthma." Journal of Immunology (1995) : 2688-2694. Picture: * DeRijk, R. H. et al. "Changes in Corticosteroid Sensitivity of Peripheral Blood Lymphocytes after Strenuous Exercise in Humans." Journal of Clinical Endocrinology and Metabolism (1996) 81: 231 Picture: * Oliver, Stephen J. et al. "Suppression of Collagen-Induced Arthritis by an Angiogenesis Inhibitor, AGM-1470, in Combination with Cyclosporin: Reduction of Vascular Endothelial Growth Factor (VEGF). Cellular Immunology (1995) Picture: * Paciotti, Giulio F. "Novel Enzyme Immunoassays for the Detection of Cytokines Interleukin 1a and Interleukin 2 in the Circulation of Normal Human Subjects: 24 Hour Profile." Progress in NeuroEndocrinImmunology (1992) 5: 21-30. Picture: * McAllister, Cathy G. "Increases in CSF Levels of Interleukin-2 in Schizophrenia: Effects of Recurrence of Psychosis and Medication Status." Am J Psychiatry (1995) 152:9: 1291-1297.
KEYWORDS:
Diagnostics Therapeutics Vaccines Cytokine BRM Diagnostic Test Kits Antibodies Monoclonal Antibody Colloidal Gold Immunology Cancer AutoImmune Disease Inflammatory Disease Bacteria Virus Neuroscience Cell Biology
RSS